Replies to post #796675 on NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

Legend431, you dropped “Roxadustat — Anemia in Chronic Kidney Disease” like it’s a mic drop. It’s not.

If you’re trying to imply that Roxadustat was published in JAMA and still rejected, then make the case. Show:

--The actual JAMA article
--The trial design and endpoints
--The reason for regulatory rejection—was it safety, manufacturing, trial flaws, or something else?
--And most importantly, how any of that parallels NWBO’s DCVax-L submission.

Because unless you can show that Roxadustat’s rejection was due to the same conditions—and that NWBO’s trial shares those flaws—you’re just name-dropping without analysis.

NWBO’s trial was randomized, double-blind, placebo-controlled, multi-country, and published in JAMA Oncology with a statistically significant survival benefit in glioblastoma. The MHRA has accepted the submission, granted manufacturing licenses, and placed DCVax-L on the HDC list for prioritized review. I bet you won’t find a drug with that profile rejected by the MHRA—because there isn’t one.

So if you’re going to use Roxadustat as a counterexample, bring receipts. Otherwise, it’s just noise. We both know.